Fairvalue-Calculator Fairvalue-Calculator
EN DE

Prime Medicine, Inc (PRME) Fair Value & Analysis

Healthcare · US · Market cap $583M

Price$3.24
Fair Value$3.01
Upside-7.1%
Quality95/100
Evidence: Low Range $2.26 – $3.76

Fair value as of: Jun 24, 2026

Analysis

Prime Medicine, Inc (PRME) currently trades at $3.24, while our model-based Fair Value estimate is $3.01 — implying the stock looks roughly 7.1% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

Prime Medicine, Inc., a biotechnology company, engages in delivering genetic medicines to address the spectrum of diseases by deploying gene editing technology in the United States. Its lead therapeutic product candidate is PM359 for Chronic Granulomatous Disease, which is in Phase 1/2 clinical trial; PM577 for Wilson Disease, that is in preclinical studies; and PM647 to treat genetic disorder caused by mutations in the SERPINA1 gene, resulting in production of misfolded Z-AAT protein that accumulates in the liver and leads to hepatocellular injury, cirrhosis, and increased risk of hepatocellular carcinoma. The company also provides vivo programs targeting diseases of the liver, and Cystic Fibrosis programs. In addition, it offers Prime Editing technology comprising a programmable DNA binding domains, such as Cas domains, are typically modified such that they do not cause a double-stranded break in the DNA, as well as a RT domain that copies the edited DNA sequence directly into the…

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -32% Regeneron Pharmaceuticals, Inc (REGN) -4% UCB SA (UCB) -27% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +9% Alnylam Pharmaceuticals, Inc (ALNY) -82%

Frequently asked questions

Is Prime Medicine, Inc (PRME) undervalued?
As of Jun 24, 2026, our model estimates a fair value of $3.01 versus a price of $3.24 — about −7% (overvalued). Model-based estimate, not financial advice.
What is the fair value of PRME?
Our 21-model fair value for Prime Medicine, Inc is $3.01 (as of Jun 24, 2026), built from audited fundamentals. The current price is $3.24.
What is the quality score of PRME?
Prime Medicine, Inc has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.